{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Effects of Neuromuscular Blocking Agents in Neurosurgical Procedures"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted at a tertiary care hospital."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adult patients aged 18-65 undergoing neurosurgery, with no history of neuromuscular disorders."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either succinylcholine or atracurium."
      },
      "Objective": {
        "score": 1,
        "evidence": "To compare the effects of succinylcholine and atracurium on intracranial pressure."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in intracranial pressure measured intraoperatively over a 2-hour period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding was applied to outcome assessors and patients."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, with 100 in each group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the succinylcholine group and 97 in the atracurium group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The mean difference in intracranial pressure was 2.5 mm Hg (95% CI 1.0 to 4.0; p = 0.03) favoring atracurium."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 5% of the succinylcholine group and 3% of the atracurium group, with no severe events."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This study was funded by the National Institute of Health."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}